What is RLAY's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.92B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RLAY?

P/E (TTM) is n/a and 52-week range is $5.85 to $21.27 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RLAY figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RLAY?

The company profile lists revenue (TTM) near $11M, net income (TTM) near $-22.51B, EPS (TTM) near $-1.57 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Relay Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 215.6M shares outstanding, ISIN US75943R1023 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Relay Therapeutics Inc (RLAY) Stock Analysis & Quote

Relay Therapeutics Inc

$RLAY

Health Care · Biotechnology

IR Run Scenarios

$17.88

+2.70%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 192 full-time employees. The company went IPO on 2020-07-16. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. The company is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

Employees

193

Website

relaytx.com/

IPO

2020-07-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)